Form 4: Third Harmonic Bio Director Acquires 60,000 Stock Options

Geoff McDonough, a director of Third Harmonic Bio, Inc., acquired 60,000 stock options on March 27, 2024, according to a Form 4 filing with the SEC.

Summary

• A Form 4 filing reveals that Geoff McDonough, a director at Third Harmonic Bio, Inc. (THRD), acquired 60,000 stock options on March 27, 2024.
• The exercise price of these options is $9.47.
• The options vest over a three-year period, starting with 1/36th vesting on April 27, 2024, and then 1/36th vesting monthly thereafter, contingent upon continued service.
• The options expire on March 26, 2034.
• Following the transaction, McDonough directly owns 60,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings provide transparency to the market and allow investors to track insider activity, which can sometimes offer insights into a company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates